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Extensive genetic alterations have been found in many epithelial malignancies. Using three 
complementary genetic approaches, Boehm et al. (2007) identify IKBKE—which encodes 
IKKε, a component of the NF-κB pathway—as a breast cancer oncogene.During malignant transformation, 
cancer cells acquire genetic altera-
tions that surmount the normal con-
trols regulating proliferation and 
cell survival. High-resolution com-
parative genomic analyses reveal 
that genomic instability is a hall-
mark of cancer development and 
that cancer-causing mutations are 
only a tiny fraction of the genetic 
modifications, most of which are 
“bystander” mutations. Thus, the 
discovery of the genetic alterations 
that contribute to tumor formation 
is crucial to the rational design of 
cancer therapeutics. But how can 
we distinguish cancer-causing 
mutations from other more benign 
mutations, and how do we identify 
genes whose activities either pro-
mote tumor development or protect 
us from cancer? In a report in this 
issue, Boehm et al. (2007) com-
bine two functional genetic screens 
together with data from compara-
tive genomic analyses to identify 
new protein kinases that promote 
tumor formation (Figure 1). These efforts have led to the identification 
of a new oncogene in breast cancer, 
IKBKE (I-kappa-B kinase epsilon), 
which encodes IKKε, an upstream 
regulator of the transcription factor 
NF-κB.Cell 129, In the first genetic screen con-
ducted by Boehm et al. (2007), a 
library of activated protein kinases 
was used in a cellular transforma-
tion system to recapitulate aspects 
of neoplastic transformation in vivo figure 1. IKBKE Is a Breast cancer Oncogene
(Left) Identification of the IKBKE gene using three different genetic approaches. (Right) The RAS on-
cogenic pathway in breast cancer. Ras-induced transformation requires deregulation of the MAPK 
and PI3K signaling pathways. The IKBKE gene product, IKKε, acts downstream of the dysregulated 
AKT kinase signaling pathway. By activating the NF-κB pathway through induction of nuclear ac-
cumulation of cRel, IKKε, together with dysregulated MAPK signaling, induces tumor growth.June 15, 2007 ©2007 Elsevier Inc. 1043
(Hahn et al., 1999). In this system, 
SV40 small t antigen and oncogenic 
RAS genes are overexpressed in 
primary human cells to stimulate 
tumorigenesis, and the p53 and 
the p16/pRb pathways are inhibited 
to prevent DNA-replication-dam-
age-induced cellular senescence 
(Bartkova et al., 2006; Di Micco et 
al., 2006). Previous studies have 
shown that new oncogenes and 
tumor suppressor genes can be 
identified using primary human 
cells genetically designed to be 
one step short of full-blown trans-
formation (Kolfschoten et al., 2005; 
Peeper et al., 2002; Voorhoeve et 
al., 2006; Westbrook et al., 2005). 
In the current study, Boehm and 
colleagues dissected the down-
stream pathways sufficient for RAS 
to induce neoplastic transforma-
tion. Although RAS can stimulate 
many pathways, such as the MAPK, 
PI3K, and RALGDS signaling path-
ways, a full-blown transformation 
phenotype of immortalized human 
cells could be acquired only by the 
simultaneous introduction of acti-
vated MEK (a kinase downstream 
of MAPK) together with a deregu-
lated (myristoylated) AKT (a kinase 
downstream of PI3K; Figure 1). This 
observation presented the authors 
with an opportunity to screen a myr-
istoylated kinase expression library 
for kinases that act in the place of 
AKT in the RAS-AKT pathway to 
promote cellular transformation. By 
doing this, the authors were able to 
identify the IKBKE gene and three 
other genes whose overexpression 
induced tumorigenesis.
In their second screen, Boehm 
et al. (2007) used an RNAi library 
designed to target 1200 kinases to 
find genes whose inactivation com-
promises cell growth and survival of 
a transformed (i.e., anchorage-inde-
pendent) human breast cancer cell 
line but not the growth of an immor-
talized nontransformed cell line. 
Several RNAi constructs were iden-
tified, and among them three (out 
of five) constructs target the IKBKE 
gene. Blocking IKBKE expression 
through RNAi impeded the prolif-
eration and survival of transformed 1044 Cell 129, June 15, 2007 ©2007 ElsMCF-7 cells but not of immortalized 
nontransformed MCF-10A cells.
These two functional genetic 
approaches yielded several can-
didate oncogenes. To identify the 
genes among those candidates that 
not only alter normal cellular behav-
ior but also are actively involved in 
human breast cancer development, 
Boehm et al. (2007) performed a 
comparative genomic analysis on a 
number of breast cancer cell lines 
and tumor specimens from cancer 
patients. Interestingly, IKBKE was 
the only candidate gene found to 
reside in a genomic region (1q32) 
that was amplified in many of the 
tumors analyzed, producing high 
expression levels of IKBKE RNA 
and protein. Furthermore, in many 
other tumor specimens, elevated 
expression of IKBKE was detected 
without being associated with gene 
amplification, indicating that sev-
eral mechanisms can upregulate 
IKBKE expression. Yet mutations 
in IKBKE were not found, suggest-
ing that IKBKE overexpression is 
more potent than activating muta-
tions. Alternatively, it is also pos-
sible that mechanisms increasing 
IKBKE expression have greater 
effects on tumorigenesis than muta-
tions or that there is a collaborating 
oncogene in the vicinity of IKBKE. 
Nonetheless, further investigation 
confirmed that IKBKE acts as an 
oncogene in breast cancer. Only 
breast cancer cell lines containing 
high IKBKE expression exhibited 
reduced viability when IKBKE levels 
were reduced by RNAi.
But how exactly does IKBKE func-
tion to promote cancer? The IKBKE 
gene product (IKKε) is a protein 
that stimulates the activity of IRF-3 
(interferon regulatory factor 3) and 
thus interferon responses to viral 
infections. Intriguingly, this function 
was not involved in the oncogenic 
capacity of IKBKE. IKKε is also 
known to activate the NF-κB signal-
ing pathway by inducing phosphor-
ylation and nuclear accumulation of 
cRel, an NF-κB component (Harris 
et al., 2006). Boehm et al. (2007) 
determined that IKKε exerts its 
oncogenic function through cRel. In evier Inc.particular, NF-κB-responsive genes 
were upregulated when IKKε was 
deregulated, IκB was destabilized, 
and nuclear accumulation of cRel 
was induced. Indeed, inhibition of 
the NF-κB pathway by overexpres-
sion of a degradation-resistant IκB 
suppressed the transforming activ-
ity of IKBKE. Activation of the NF-
κB pathway has been observed in 
many breast cancers, but a molecu-
lar explanation for this activation 
has not been clear. The identifica-
tion by Boehm et al. (2007) of IKBKE 
as an oncogene and activator of the 
NF-κB pathway in breast cancer 
explains this observation.
Could IKKε be a potential target 
for cancer therapy? Developing 
and testing inhibitors that block 
activity of IKKε should be an inter-
esting future strategy for treating 
breast cancer. Obviously, the spe-
cificity and toxicity of such inhibi-
tors will determine the success of 
this strategy. It is promising that 
blocking IKBKE expression affected 
only the viability of cancer cells 
with deregulated IKBKE expres-
sion. Interestingly, IKBKE has a 
very close homolog called TBK1. 
Although breast cancer cell lines 
showed dependence on IKBKE, 
some prostate tumor cell lines were 
sensitive to inhibition of TBK1 activ-
ity. Whether TBK1 is an oncogene in 
prostate cancer, in a manner simi-
lar to IKBKE’s oncogenic effects in 
breast cancer, awaits further study. 
The similarity between these two 
kinases also suggests that tumor 
cells treated with IKBKE inhibitors 
could rapidly develop drug resist-
ance through upregulation of TBK1. 
Therefore, the best approach may 
be to develop an inhibitor capable 
of blocking the activity of both the 
IKKε and TBK1 kinases.
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HSCs are known to reside in two differ-
ent niches, an “osteoblastic” niche and 
a “vascular” niche. In the osteoblastic 
niche, HSCs are associated with a sub-
set of osteoblasts (the cells responsible 
for bone formation) that line the inner 
surface of the bone cavity (Calvi et al., 
2003; Zhang et al., 2003; Arai et al., 
2004). In contrast, in the vascular niche, 
HSCs associate with the surfaces of 
endothelial cells that line the sinusoids 
of bone marrow and spleen (Kiel et 
al., 2005). Recently, it was shown that 
CXCL12-abundant reticular (CAR) cells 
are found in association with HSCs 
in both the osteoblastic and vascular 
niches (Sugiyama et al., 2006) and may 
serve as a transit pathway for shuttling 
HSCs between the two. It has been 
proposed that these two niches are 
functionally distinct: the osteoblastic 
niche is thought to maintain HSC qui-
escence over the long term, whereas 
the vascular niche is thought to main-
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differentiation, and mediating HSC 
circulation (Kopp et al., 2005). Despite 
the critical role of these two niches in 
regulating HSCs, evidence for a role of 
the niche in disease has been limited. 
In this issue of Cell, Orkin, Purton, and 
their colleagues demonstrate in mice 
that the microenvironment can play a 
dominant role in the development of 
myeloproliferative disease—a disorder 
characterized by the neoplastic devel-
opment of myeloid cells (Walkley et al., 
2007a, 2007b) (Figure 1).
Given that key cell cycle regula-
tors have been implicated in HSC 
dysfunction, Orkin and colleagues 
first examined loss of the retinoblas-
toma (RB) protein, a cell cycle regu-
lator and tumor suppressor, in the 
hematopoietic system (Walkley et al., 
2007a). Surprisingly, RB was found to 
be dispensable for self-renewal and 
multilineage differentiation of HSCs. 
However, widespread loss of RB in the 
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hematopoietic system results in extra-
medullary hematopoiesis (hematopoi-
esis outside of the bone marrow, for 
instance, in the spleen). These mice 
eventually develop myeloproliferative 
disease. Strikingly, myeloid-specific 
loss of RB resulted in only mild defects 
and did not result in myeloprolifera-
tive disease or HSC abnormalities, 
suggesting that the defect resulting 
from widespread loss of RB is not 
solely caused by myeloid cells with 
intrinsic RB deficiency or by myeloid 
cells derived from RB-deficient HSCs. 
Furthermore, transplantation of nor-
mal hematopoietic cells into an RB-
deficient microenvironment failed to 
recapitulate the effects observed with 
widespread deletion of RB. Only when 
myeloid-specific loss of RB was com-
bined with loss of RB in the microenvi-
ronment was the full myeloproliferative 
defect recapitulated. Thus, the myelo-
proliferative disease observed with 
widespread loss of RB resulted from 
an interaction between myeloid cells 
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